Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma

Sneha Berry, Janis M. Taube

Research output: Contribution to journalArticlepeer-review

Abstract

Oncogenic driver mutations in several tumor types promote constitutive PD-L1 expression, a crucial ligand in PD-1-mediated tumor immune escape. Our studies in melanoma suggest a different mechanism–one of “adaptive immune resistance” in which PD-L1 expression is primarily driven by cytokine induction and is independent of BRAF mutational status.

Original languageEnglish (US)
JournalOncoImmunology
Volume4
Issue number10
DOIs
StatePublished - Oct 3 2015

Keywords

  • BRAF
  • PD-L1
  • TIL
  • adaptive immune resistance
  • melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma'. Together they form a unique fingerprint.

Cite this